Co-Authors
This is a "connection" page, showing publications co-authored by PETER F THALL and YING YUAN.
Connection Strength
1.768
-
Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes. Clin Cancer Res. 2023 11 14; 29(22):4549-4554.
Score: 0.243
-
A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharm Stat. 2023 01; 22(1):34-44.
Score: 0.221
-
Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. JCO Precis Oncol. 2021; 5.
Score: 0.211
-
BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons. J Am Stat Assoc. 2021; 116(533):322-334.
Score: 0.198
-
A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Anal. 2021 Mar; 16(1):179-202.
Score: 0.189
-
An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics. 2020 03; 76(1):304-315.
Score: 0.182
-
A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes. J Am Stat Assoc. 2018; 113(523):1255-1267.
Score: 0.170
-
Utility-based designs for randomized comparative trials with categorical outcomes. Stat Med. 2016 10 30; 35(24):4285-4305.
Score: 0.144
-
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 Dec; 24(12):1387-1398.
Score: 0.061
-
BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. Ann Appl Stat. 2022 Dec; 16(4):2481-2504.
Score: 0.056
-
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
Score: 0.054
-
Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. J Am Stat Assoc. 2017; 112:11-23.
Score: 0.039